RELIEF THERAPEUTICS HLDG AG RLFTF overview

GENEVA, SWITZERLAND / ACCESSWIRE / September 18, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that it has completed dosing in its proof-of-concept clinical study of RLF-OD032 for the treatment of phenylketonuria (PKU), a rare inherited disorder affecting phenylalanine metabolism. The primary...

Relief Therapeutics Holding SA / Key word(s): Study Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024 18.09.2024 / 07:00 CET/CEST Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024 GENEVA (SEPT. 18, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF , OTCQB: RLFTF , RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering...

GENEVA, SWITZERLAND / ACCESSWIRE / September 2, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, announced today that interim data from its clinical trial evaluating PKU GOLIKE ® will be presented at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium being held in Porto,...

Relief Therapeutics Holding SA / Key word(s): Study Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 02.09.2024 / 07:00 CET/CEST Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 GENEVA (SEPT. 2, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF , OTCQB: RLFTF , RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, announced...

RLF-TD011 investigator-initiated trial results for EB wound treatment anticipated in the coming weeks RLF-OD032 pilot PK study progresses with potential NDA filing by mid- to late 2025 Streamlined operations and CHF 15.1 million cash reserves expected to provide funding into at least 2026 GENEVA, SWITZERLAND / ACCESSWIRE / August 30, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering...

Relief Therapeutics Holding SA / Key word(s): Half Year Results Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update 30-Aug-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update RLF-TD011 investigator-initiated trial results for EB wound treatment anticipated in the coming...

Non-dilutive funding to support RLF-TD011 clinical development and pipeline advancement GENEVA, SWITZERLAND / ACCESSWIRE / August 5, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced the signing and closing of a definitive agreement with SWK Funding LLC (SWK), a wholly-owned subsidiary of SWK...

Relief Therapeutics Holding SA / Key word(s): Miscellaneous Relief Therapeutics Secures up to $11 Million from Royalty Sales 05-Aug-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Relief Therapeutics Secures up to $11 Million from Royalty Sales Non-dilutive funding to support RLF-TD011 clinical development and pipeline advancement GENEVA (Aug. 5, 2024) – RELIEF THERAPEUTICS Holding SA (SIX:...